Loading...
Although continuous infliximab therapy is optimal for the treatment of Crohn disease, intermittent therapy is often used, increasing the likelihood of antibodies to infliximab (ATIs). These antibodies can shorten the duration of response to infliximab and raise the risk for infusion reactions. Concomitant use of immunosuppressants with infliximab can reduce the risk for ATI formation, but we do not yet know which of two commonly used immunosuppressants is most effective in this role: methotrexate or azathioprine.
To address this issue, researchers conducted a prospective multicenter study among 174 Crohn disease patients in Belgium. All the study participants received infliximab on an intermittent (on-demand) basis. Sixty-five patients recei…